We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection.
Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. We plan to commercially launch Galleri in 2021 as a laboratory developed test. In a clinical study, an earlier version of Galleri identified over 50 types of cancers, over 45 of which lack recommended screenings. (These cancers include cancer of the bladder, the anorectal area, the esophagus, the pancreas , the liver, the ovary and the uterus, as well as melanoma.) Data showed that when our test detected a cancer, it was also able to localize the cancer signal with high accuracy.
|Industry:||Services - Medical Laboratories|
|Address||1525 O’Brien Drive Menlo Park, California 94025|
|Phone Number||(650) 542-0372|
|View Prospectus:||GRAIL, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-264.1 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$100.0 mil|
|Manager / Joint Managers||Morgan Stanley/ Goldman Sachs/ BofA Securities/ Cowen/ Evercore ISI|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|